Details
Home
Trade Portal
CEFTA
Customs
Product Requirements
Services
Intellectual Property Rights
Public Procurement
Trade Facilitation and Exchange of Electronic Data
Investing within CEFTA
EU
The EU Single Market
Customs and tariffs
EU - CEFTA trade relations
Rules of origin
Product requirements in the EU
Taxes
Customs clearance documents and procedures
Intellectual property rights
Services
Public procurement
SPS Database
Search SPS Database
Reports
Laboratories
Memberships of international organizations
Food and feed producers / Importers / Warehouses
Food export Establishment
Agricultural support
Certificates in use
Bilateral and International Agreements
Customs tariffs
TBT Platform
Search TBT Database
Quality Infrastructure
Accreditation
Standardization
Conformity Assessment
Metrology
Market Surveillance
MABD
Reports
BTI Database
Services Regulatory
Database
Measures in Services
Notifications
Statistical Portal
Trade in Goods
Trade in Services
Foreign Direct Investment
Foreign Affiliates Trade Statistics
Raw Data Export
Indicators
Macroeconomic Data
Reports
Market surveillance
Product safety
Authorized Economic Operator
Recognized AEOs
Login
Back
Previous Record
Next Record
Issuing CEFTA Economy
Serbia
BTI Reference
1840/17
Validity Start Date
19/01/2017
Validity End Date
19/01/2020
Nomenclature code
3002150000
Justification
Language
Српски језик
Issuing place
Beograd
Issuing date
Goods description
Imunološki proizvod (lek), pripremljen u pakovanju za prodaju na malo. Predmetna roba je u vidu liofilizovanog praha, upakovanog u staklenu bocicu, koja se uz uputstvo za upotrebu isporucuje u kartonskoj kutiji sa naštampanom proizvodackom deklaracijom. Proizvod sadrži infliksimab (himerno monoklonsko antitelo) 100 mg, kao aktivnu komponentu, i pomocne supstance: polisorbat 80, saharozu, natrijum dihidrogenfosfat, monohidrat i dinatrijum fosfat, dihidrat. Nakon rekonstitucije, 1 ml rastvora sadrži 10 mg infliksimaba. Primenjuje se putem intravenske infuzije, nakon rekonstitucije dodatkom vode za injekcije, u lecenju reumatoidnog i psorijaticnog artritisa, ankilozirajuceg spondilitisa i psorijaze, kod odraslih osoba, kao i u lecenju Kronove bolesti i ulceroznog kolitisa, kod odraslih i dece starosti 6 godina i više. Terapeutsko dejstvo leka (pripada grupi „TNF blokatora“) se zasniva na sprecavanju delovanja proteina TNFa, koji ucestvuje u zapaljenskim procesima u organizmu.
National keywords
Imunološki proizvod (lek)
Uploaded Documents
Export to PDF
×